Recurium IP Holdings, LLC

Firmenich Incorporated

Exelixis Patent Company LLC

Senomyx, Inc.

Brant Clayton Boren

Donald Karanewsky

Kevin Duane Bunker

Wen Zhao

Raju Mohan

Peter Qinhua Huang

Andrew P Patron

Jane Ung

Chad Priest

Alain Noncovich

Jeffrey Robert Hammaker

Rachel Kimmich

Volodymyr Chumakov

Lyudmyla Chumakova

Michael M Morrissey

Richard Martin

Sunil Paliwal

Venkataiah Bollu

Tie-Lin Wang

Brenton Todd Flatt

Sunny Abraham

Chad Daniel Hopkins

Benjamin Pratt

Xiao-Hui Gu

Jackaline Dalgard Julien

Hui Liu

Nadia Haq

Aditya Krishnan Unni

Sarah Hudson

Wei Xu

Catherine Tachdjian

Guy Servant

Mehmet Kahraman

Hong Zhang

Qing Chen

Joseph Robert Pinchman

Vasu Jammalamadaka

Joseph R Fotsing

Brett Bradley Busch

Sayee Gajanan Hegde

Deborah Helen Slee

Edwin J Schweiger

William C Stevens, Jr

Yinong Xie

Goran Petrovic

Shao Po Lu

Brett Weylan Ching

Shao-Po Lu

Binh Vong

Stephanie Lapera

Sobhana Babu Boga

Donald S Karanewsky

Disclosed herein are methods for preparing tertiary alcohols from an optionally substituted phenyl ketone or an optionally substituted pyridinyl ketone that includes the use of a chiral ligand and boron trifluoride diethyl etherate. Tertiary alcohols can be used to prepare synthetic versions of natural products and/or pharmaceuticals.

Chiral synthesis of a tertiary alcohol

Disclosed herein are 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acid compounds having useful as sweet flavor modifiers. Also disclosed herein are ingestible compositions that include one or more of these compounds in combination with a natural or artificial sweetener.

Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones

Disclosed herein are compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), and methods of using compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It) as an analgesic.

Analgesic compounds

L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs

The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formulae (Ia), (Ib) and (Ic), and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations. 

Compounds useful as modulators of TRPM8

TGR5 agonists of structural formula VIII(Q), wherein X, R, R, and Rare defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases. 

TGR5 agonists

The present invention comprises TGR5 agonists of structural formula I, wherein X, R, R, and Rare defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.

Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity

Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R, R, R, R, J, J, G, G, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. 

LXR and FXR modulators

Growing community of inventors

San Diego, CA, United States of America

Brant Clayton Boren